Journal of Rheumatology最新文献

{"title":"A Rare Case of Parvovirus B19-Induced Atlantoaxial Arthritis.","authors":"Cristina Valero-Martínez","doi":"10.3899/jrheum.2024-1293","DOIUrl":"https://doi.org/10.3899/jrheum.2024-1293","url":null,"abstract":"","PeriodicalId":50064,"journal":{"name":"Journal of Rheumatology","volume":" ","pages":""},"PeriodicalIF":3.6,"publicationDate":"2025-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143634694","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Application of EULAR/ACR Classification Criteria for Polymyalgia Rheumatica in a Series of Patients With Acute Parvovirus B19 Infection.","authors":"Bernardo D'Onofrio, Carlo Selmi","doi":"10.3899/jrheum.2024-1024","DOIUrl":"https://doi.org/10.3899/jrheum.2024-1024","url":null,"abstract":"","PeriodicalId":50064,"journal":{"name":"Journal of Rheumatology","volume":" ","pages":""},"PeriodicalIF":3.6,"publicationDate":"2025-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143634709","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diversity in Axial Spondyloarthritis Drug Trials: Enrollment by Sex, Race, Ethnicity, and Geographic Region.","authors":"Mathieu Choufani, Wissam Ghusn, Maureen Dubreuil, Joerg Ermann","doi":"10.3899/jrheum.2024-1013","DOIUrl":"https://doi.org/10.3899/jrheum.2024-1013","url":null,"abstract":"<p><strong>Objective: </strong>To examine demographic and geographic diversity in axial spondyloarthritis (axSpA) drug trials.</p><p><strong>Methods: </strong>We performed a descriptive epidemiological study using ClinicalTrials.gov data. We included completed phase II-IV drug trials in adults with axSpA, conducted between 2000 and 2023, with results posted on ClinicalTrials.gov. We extracted and analyzed data on sex, race, ethnicity, trial characteristics and trial locations.</p><p><strong>Results: </strong>59 trials with 16,162 participants were analyzed. Females constituted 30% of participants overall: 25% in AS/r-axSpA trials, 34% in axSpA trials, and 48% in nr-axSpA trials. 31 trials (53%) reported race, and 12 (20%) reported both race and ethnicity. Race reporting increased from 9% of trials (2000-2010) to 53% (2011-2015) and 100% (2016-2020). Among 10,037 participants with race data, 82% were White, 15% Asian, 2% American Indian/Alaska Native, 1% Black, and 0.02% Native Hawaiian/Pacific Islander. Asian representation increased from 4% (2011-2015) to 19% (2016-2020), American Indian/Alaska Native from 1% to 3%, while Black representation remained consistently low at 1%. Among 3,577 patients with ethnicity data, 14% of participants were Hispanic/Latino, increasing from 1% (2011-2015) to 14% (2016-2020). 51 trials with location data enrolled participants from 53 countries. Sub-Saharan Africa (0%) and South/Central Asia (2%) had the lowest geographic representation of enrollment sites.</p><p><strong>Conclusion: </strong>The enrollment of women in axSpA drug trials largely reflects disease demographics. Race and ethnicity reporting has improved over time. While participation of Asian, American Indian/Alaska Native and Hispanic/Latino patients has increased, Black and Native Hawaiian/Pacific Islander representation has remained low. Future efforts should prioritize inclusivity and participation in underrepresented regions globally.</p>","PeriodicalId":50064,"journal":{"name":"Journal of Rheumatology","volume":" ","pages":""},"PeriodicalIF":3.6,"publicationDate":"2025-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143634765","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of Age on Active and Structural Magnetic Resonance Imaging Lesions in Sacroiliac Joints of Healthy Individuals and Patients With Nonspecific Back Pain.","authors":"Ulrich Weber, Sengül Seven, Susanne J Pedersen, Mikkel Østergaard, Pedro M Machado, Stephanie Wichuk, Xenofon Baraliakos, Robert G W Lambert, Walter P Maksymowych","doi":"10.3899/jrheum.2024-0563","DOIUrl":"10.3899/jrheum.2024-0563","url":null,"abstract":"<p><strong>Objective: </strong>To assess the effect of increasing age on the frequency of inflammatory and structural magnetic resonance imaging (MRI) lesions in the sacroiliac joints (SIJ) in 3 independent cohorts of healthy individuals and patients with nonspecific back pain (NSBP).</p><p><strong>Methods: </strong>We assessed MRI SIJ lesions in 3 cohorts (A, B, and C) of healthy individuals (cohort A, n = 79; cohort B, n = 78) and patients with NSBP (cohort A, n = 87; cohort C, n = 46) aged ≤ 45 years referred with back pain suspicious of axial spondyloarthritis (axSpA). MRI lesions were recorded on consecutive slices in SIJ quadrants or halves through the cartilaginous SIJ. Lesions were ascertained by 2-7 central readers according to standardized lesion definitions. Lesions recorded concordantly by the majority of readers were analyzed according to age categories (18-29, 30-39, and 40-50 yrs) and previously reported data-driven MRI cutoffs indicative of inflammatory or structural lesions typical of axSpA.</p><p><strong>Results: </strong>Only 3.8% (in both cohort A and cohort B) of healthy individuals and 5.7% (cohort A) and 4.3% (cohort C) of patients with NSBP had erosion in ≥ 1 SIJ quadrant, and progressive increases of erosion with age categories were not evident. None of the healthy individuals and 2.3% and 4.3% of cohort A and cohort C, respectively, of the patients with NSBP showed erosion in ≥ 3 SIJ quadrants, the cutoff indicative of axSpA; not a single individual met this cutoff in the highest age category. Fat metaplasia was slightly increased with age among healthy individuals and patients with NSBP in cohort A, but not in cohorts B or C.</p><p><strong>Conclusion: </strong>SIJ MRI data from healthy individuals and NSBP controls did not indicate progressive increases in structural lesions with increasing age categories when standardized definitions for axSpA lesions were adopted. MRI cutoffs for structural lesions denoting axSpA discriminated equally well between axSpA and NSBP across all age categories.</p>","PeriodicalId":50064,"journal":{"name":"Journal of Rheumatology","volume":" ","pages":""},"PeriodicalIF":3.6,"publicationDate":"2025-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143076097","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Managing Giant Cell Arteritis With Tocilizumab: Relapses and Adverse Events.","authors":"Miguel Ángel González-Gay, Santos Castañeda, Iván Ferraz-Amaro","doi":"10.3899/jrheum.2024-1204","DOIUrl":"10.3899/jrheum.2024-1204","url":null,"abstract":"","PeriodicalId":50064,"journal":{"name":"Journal of Rheumatology","volume":" ","pages":"206-209"},"PeriodicalIF":3.6,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142840053","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Trial.","authors":"Victor S Sloan, Lois Wingerson, Christopher Adams","doi":"10.3899/jrheum.2024-1052","DOIUrl":"10.3899/jrheum.2024-1052","url":null,"abstract":"","PeriodicalId":50064,"journal":{"name":"Journal of Rheumatology","volume":" ","pages":"290-291"},"PeriodicalIF":3.6,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142840059","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Unacceptable Work State in Rheumatoid Arthritis: Establishment of Thresholds for Presenteeism and Clinical Measurement Instruments.","authors":"Dafne Capelusnik, Sofia Ramiro, Elena Nikiphorou, Walter P Maksymowych, Marina Nighat Magrey, Helena Marzo-Ortega, Annelies Boonen","doi":"10.3899/jrheum.2024-0833","DOIUrl":"10.3899/jrheum.2024-0833","url":null,"abstract":"<p><strong>Objective: </strong>We aimed to identify threshold values of presenteeism measurement instruments that reflect unacceptable work state in employed patients with rheumatoid arthritis (RA) and whether those thresholds can predict future adverse work outcomes (AWOs). Additionally, we assessed the performance of presenteeism thresholds previously established in axial spondyloarthritis (axSpA) among patients with RA for the same instruments.</p><p><strong>Methods: </strong>Data from the multinational Patient-Reported Outcomes in Employment Study in Rheumatoid Arthritis (RA-PROSE) study were used. Thresholds to determine when patients consider themselves in an \"unacceptable work state\" were calculated at baseline for 4 instruments assessing presenteeism and for the patient global assessment of RA-related pain. Different approaches derived from the receiver-operating characteristic methodology were used. Accuracy of thresholds to predict AWO throughout 12 months was assessed and previously developed presenteeism thresholds for axSpA were also tested.</p><p><strong>Results: </strong>A total of 104 employed patients were included: 15% of the patients considered themselves in an unacceptable work state, of which 7 (7%) had at least 1 AWO over 12 months. Thresholds of all instruments specifically developed in RA showed good performance vs the external criterion (area under the curve [AUC] > 0.75), except for the Quantity and Quality (QQ) method (AUC 0.62). The available axSpA thresholds were more accurate by reducing overestimation. The final optimal thresholds were Work Productivity and Activity Impairment Questionnaire (WPAI)-presenteeism ≥ 40, QQ method < 97, Workplace Activity Limitations Scale ≥ 0.75, 25-item Work Limitations Questionnaire with modified physical demands scale ≥ 29, and pain intensity ≥ 4. For AWO over 12 months, pain and WPAI performed best in predicting AWO.</p><p><strong>Conclusion: </strong>The final thresholds to assess unacceptable presenteeism for axSpA were also chosen as most accurate for use in RA. In addition, accurate thresholds of pain reflecting unacceptable work state are available.</p>","PeriodicalId":50064,"journal":{"name":"Journal of Rheumatology","volume":" ","pages":""},"PeriodicalIF":3.6,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143076131","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of Myocarditis in Patients With Still Disease: Clinical Findings From the Multicenter International AIDA Network Still Disease Registry.","authors":"Piero Ruscitti, Ilenia Di Cola, Antonio Vitale, Valeria Caggiano, Pierpaolo Palumbo, Ernesto Di Cesare, Jiram Torres-Ruiz, Guillermo Arturo Guaracha-Basañez, Eduardo Martín-Nares, Francesco Ciccia, Daniela Iacono, Flavia Riccio, Maria Cristina Maggio, Samar Tharwat, Soad Hashad, Donato Rigante, Augusta Ortolan, Henrique A Mayrink Giardini, Isabele Parente de Brito Antonelli, Rafael Alves Cordeiro, Roberto Giacomelli, Luca Navarini, Onorina Berardicurti, Alessandro Conforti, Daniela Opris-Belinski, Jurgen Sota, Carla Gaggiano, Giuseppe Lopalco, Fiorenzo Iannone, Francesco La Torre, Violetta Mastrorilli, Marcello Govoni, Francesca Ruffilli, Giacomo Emmi, Edoardo Biancalana, Petros P Sfikakis, Maria Tektonidou, José Hernández-Rodríguez, Verónica Gómez-Caverzaschi, Özgül Soysal Gündüz, Giovanni Conti, Serena Patroniti, Antonio Gidaro, Arianna Bartoli, Alma Nunzia Olivieri, M Francesca Gicchino, Antonio Luca Brucato, Lorenzo Dagna, Alessandro Tomelleri, Corrado Campochiaro, Amato De Paulis, Ilaria Mormile, Francesca Della Casa, Haner Direskeneli, Fatma Alibaz-Oner, Anastasios Karamanakos, Aikaterini Dimouli, Gaafar Ragab, Ayman Abdelmonem Ahmed Mahmoud, Abdurrahman Tufan, Hamit Kucuk, Riza Kardas, Ezgi D Batu, Seza Ozen, Ewa Wiesik-Szewczyk, Andrea Hinojosa-Azaola, Alberto Balistreri, Claudia Fabiani, Bruno Frediani, Luca Cantarini","doi":"10.3899/jrheum.2024-0683","DOIUrl":"10.3899/jrheum.2024-0683","url":null,"abstract":"<p><strong>Objective: </strong>We aimed to (1) evaluate the cardiac involvement, with a focus on myocarditis, in patients with Still disease included in the multicenter Autoinflammatory Disease Alliance (AIDA) Network Still disease registry; and (2) assess the predictive factors for myocarditis by deriving a clinical risk patient profile for this severe manifestation.</p><p><strong>Methods: </strong>A multicenter observational study was established, in which consecutive patients with Still disease in the AIDA Network Still disease registry were characterized by cardiac involvement. Cardiac involvement was defined according to the presence of pericarditis, tamponade, myocarditis, and/or aseptic endocarditis.</p><p><strong>Results: </strong>In total, 73 patients with Still disease and cardiac involvement were assessed (mean age 36.3 [SD 19.9] years; male sex, 42.5%), out of which 21.9% were children. The most common cardiac manifestation was pericarditis, occurring in 90.4% of patients; patients also presented with myocarditis (26%), and less frequently endocarditis (2.7%) and tamponade (1.4%). In comparing clinical features of patients with myocarditis to those without, significantly increased frequencies of skin rash and pleuritis, as well as higher systemic scores, were seen. Further, a higher mortality rate was shown in patients with myocarditis. In regression models, skin rash and the systemic score independently predicted the myocarditis.</p><p><strong>Conclusion: </strong>The characteristics of patients with Still disease and cardiac involvement were assessed in the AIDA Network. The most common feature was the pericarditis, but a more severe clinical picture was also reported in patients with myocarditis. The latter was associated with increased mortality rate and higher systemic score, identifying patients who should be carefully managed.</p>","PeriodicalId":50064,"journal":{"name":"Journal of Rheumatology","volume":" ","pages":"226-233"},"PeriodicalIF":3.6,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142640141","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"High-Sensitivity Cardiac Troponin T as a Marker to Improve Cardiovascular Disease Risk Assessment Among Patients With Rheumatoid Arthritis.","authors":"Gang Wang, Zhichun Liu","doi":"10.3899/jrheum.2024-0723","DOIUrl":"10.3899/jrheum.2024-0723","url":null,"abstract":"","PeriodicalId":50064,"journal":{"name":"Journal of Rheumatology","volume":" ","pages":"295"},"PeriodicalIF":3.6,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142840044","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of Bimekizumab on Patient-Reported Outcomes and Work Productivity in Patients With Psoriatic Arthritis: 1-Year Results From 2 Phase III Studies.","authors":"Dafna D Gladman, Philip J Mease, Laure Gossec, M Elaine Husni, Alice B Gottlieb, Barbara Ink, Rajan Bajracharya, Jason Coarse, Nikos Lyris, Jérémy Lambert, William Tillett","doi":"10.3899/jrheum.2024-0923","DOIUrl":"10.3899/jrheum.2024-0923","url":null,"abstract":"<p><strong>Objective: </strong>To assess the longer-term effect of bimekizumab up to 1 year on patient-reported symptoms, health-related quality of life (HRQOL), and work productivity in patients with active PsA who were biologic disease-modifying antirheumatic drug (bDMARD)-naïve or had inadequate response/intolerance to tumor necrosis factor inhibitors (TNFi-IR).</p><p><strong>Methods: </strong>BE OPTIMAL (ClinicalTrials.gov: NCT03895203; bDMARD-naïve patients) and BE COMPLETE (NCT03896581; TNFi-IR patients) are phase III studies of subcutaneous bimekizumab 160 mg every 4 weeks. Both studies were double-blind and placebo-controlled to 16 weeks. Patients who completed week 52 of BE OPTIMAL or week 16 of BE COMPLETE were eligible for the open-label extension, BE VITAL (NCT04009499), during which all patients received bimekizumab. Patient-reported pain, fatigue, physical function, HRQOL, and work productivity are reported to week 52 or 40 (52/40) using individual study data for bimekizumab and placebo treatment arms.</p><p><strong>Results: </strong>Bimekizumab-randomized patients demonstrated sustained mean improvements from baseline in patient-reported outcomes to week 52/40, including pain (visual analog scale [0-100 mm]: bDMARD-naïve -30.5; TNFi-IR -31.8), fatigue (Functional Assessment of Chronic Illness Therapy-Fatigue scale [0-52]: bDMARD-naïve 5.3; TNFi-IR 6.0), physical function (Health Assessment Questionnaire-Disability Index [0-3]: bDMARD-naïve -0.34; TNFi-IR -0.39), and HRQOL (36-item Short Form Health Survey, physical component summary: bDMARD-naïve 8.1; TNFi-IR 8.4); placebo patients who switched to bimekizumab at week 16 demonstrated comparable levels of improvement from week 16 to week 52/40. Improvements in overall work impairment were sustained among bimekizumab-randomized patients to week 52. Similar trends were observed for absenteeism, presenteeism, and activity impairment.</p><p><strong>Conclusion: </strong>Bimekizumab treatment resulted in sustained improvements in patient-reported symptoms, HRQOL, and work productivity up to 1 year in bDMARD-naïve and TNFi-IR patients with active PsA.</p>","PeriodicalId":50064,"journal":{"name":"Journal of Rheumatology","volume":" ","pages":""},"PeriodicalIF":3.6,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143076086","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}